NasdaqGS:ONCBiotechs
HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC)
BeOne Medicines recently presented full Phase 3 HERIZON-GEA-01 results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2-positive gastroesophageal adenocarcinoma at the 2026 ASCO GI Cancers Symposium in San Francisco, including an interim overall survival analysis.
The regimen’s high overall response rate and prolonged median duration of response, combined with BeOne’s commercial rights to ZIIHERA across much of Asia Pacific, elevate the potential...